Related Experiment Video
Updated: Jul 13, 2026
08:13
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Published on: January 7, 2018
Hepatobiliary diseases and insulin resistance
Nahum Méndez-Sánchez1, Noberto C Chávez-Tapia, D Zamora-Valdés
1Department of Biomedical Research, Medica Sur Clinic & Foundation, Mexico City, Mexico. nmendez@medicasur.org.mx
Current Medicinal Chemistry
|August 21, 2007
Summary
Obesity is linked to liver and biliary diseases through insulin resistance. This review explores the molecular pathways connecting insulin resistance, fat accumulation, and inflammation in these conditions.
Area of Science:
- Hepatology
- Metabolic Syndrome
- Molecular Biology
Background:
- Rising obesity rates correlate with increased hepatic and biliary diseases.
- Insulin resistance is a key mechanism linking obesity to liver and biliary conditions.
- Obesity-related insulin resistance impacts gallstone disease, nonalcoholic fatty liver disease, and hepatitis C outcomes.
Purpose of the Study:
- To review the molecular and biochemical pathways in hepatic and biliary diseases associated with insulin resistance.
- To elucidate the mechanisms of fat-induced hepatic insulin resistance.
- To summarize the link between insulin resistance, inflammation, and liver disease.
Main Methods:
- Literature review of epidemiological, clinical, and basic research.
- Analysis of molecular signaling pathways involved in insulin resistance.
- Examination of biochemical changes in hepatocytes during insulin resistance.
Main Results:
- Insulin resistance impairs hepatic glucose regulation and promotes fat accumulation in hepatocytes.
- Fat accumulation results from increased lipolysis, fatty acid uptake, and triglyceride synthesis.
- Molecular signaling in insulin resistance triggers a chronic inflammatory state with elevated proinflammatory molecules.
Conclusions:
- Insulin resistance is central to the pathogenesis of obesity-related hepatic and biliary diseases.
- Understanding these molecular mechanisms is crucial for developing targeted therapies.
- Further research into insulin signaling and inflammation is warranted.
Related Concept Videos
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...